Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2022 on file Net Income-$6.03M-$6.03MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,965,000— Operating Cash Flowderived-$4,970,000N/M Free Cash Flowderived-$5,476,000N/M ended Jun 30, 2023 · filed Sep 27, 2023 · 89 d after period end